Odyssey Health, Inc.

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully close on the sub-license agreement. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company’s ability to advance the development and commercialization of the BreastCheck® under the timelines and in accord with the milestones projected; the Company’s ability to raise capital and obtain funding, non-dilutive or otherwise, for the development and commercialization of the BreastCheck®; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the Company’s expectations as to the outcome of the potential benefits, effectiveness and safety of the BreastCheck® including as to administration, manufacturing, distribution and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements.

On October 16, 2025, the Company issued a press release announcing the signing of the Master Technology and Sub-license Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.